Korro Bio dosed first participants in Phase 1/2a study of KRRO-110 for AATD; interim data H2 2025

Korro Bio, Inc.

First participants dosed in REWRITE Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD).
Interim data from Part 1 (single ascending doses) expected H2 2025; study completion anticipated in 2026.
Pipeline update: Korro targets 3 candidates, 2 tissue types, single platform (3-2-1 strategy) by 2027.
Novo Nordisk partnered program in cardiometabolic indication progressing towards clinic.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.